Fighting overtreatment in adjuvant breast cancer therapy

@article{Gnant2010FightingOI,
  title={Fighting overtreatment in adjuvant breast cancer therapy},
  author={M. Gnant and G. Steger},
  journal={The Lancet},
  year={2010},
  volume={374},
  pages={2029-2030}
}
In The Lancet today, Kathy Albain and colleagues present 10-year results of the SWOG-8814 (INT-0100) trial, which since its fi rst presentation has defi ned a standard of care in breast cancer—ie, adjuvant cytotoxic chemotherapy is benefi cial for node-positive patients. However, use of nodal status as the main prognostic factor leads to huge overtreatment for many patients. Even in today’s paper, the absolute 10-year overall survival diff erence was just 5%, more than enough to justify a… Expand
Dual inhibition of HER2 in breast cancer treatment
Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?
Modern Therapeutic Concepts of Early Breast Cancer
Adjuvant endocrine therapy alone in patients with node-positive, luminal A type breast cancer
Guidelines: Usefulness and Limitations
  • M. Gnant
  • Computer Science, Medicine
  • Breast Care
  • 2013
Breast Cancer Genomics
...
1
2
3
4
...

References

SHOWING 1-9 OF 9 REFERENCES
New results from the use of bisphosphonates in cancer patients
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Gene-expression signatures in breast cancer.